Significance of urokinase-type plasminogen activator and plasminogen activator inhibitor-1 (PAI-1) expression in human colorectal carcinomas

Tumor Biology

Volumn 23, Issue 3, 2002, Pages 170-178

  Papadopoulou, S ^a   Scorilas, A ^b   Yotis, J ^a   Arnogianaki, N ^a   Plataniotis, G ^a   Agnanti, N ^c   Talieri, M ^a  

^a SAINT SAVVAS HOSPITAL   (Greece)

^b INSTITUTE OF NANOSCIENCE AND NANOTECHNOLOGY   (Greece)

^c UNIVERSITY OF IOANNINA   (Greece)

Author keywords

Colon cancer; Urokinase plasminogen activator inhibitor; Urokinase type plasminogen activator

Indexed keywords

ANTIGEN; PLASMINOGEN ACTIVATOR INHIBITOR 1; UROKINASE;

ADENOCARCINOMA; ADENOMA; ADULT; ARTICLE; CANCER CLASSIFICATION; CANCER GRADING; CANCER STAGING; CANCER TISSUE; COLON; COLORECTAL CARCINOMA; COLORECTAL TUMOR; CONTROLLED STUDY; CORRELATION ANALYSIS; DUKES STAGE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE; MAJOR CLINICAL STUDY; MALE; MUCOSA; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; STROMA CELL; AGED; CARCINOMA; ENZYMOLOGY; METABOLISM; MIDDLE AGED;

ADULT; AGED; CARCINOMA; COLON; COLORECTAL NEOPLASMS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; PLASMINOGEN ACTIVATOR INHIBITOR 1; URINARY PLASMINOGEN ACTIVATOR;

EID: 0036559388     PISSN: 10104283     EISSN: None     Source Type: Journal    
DOI: 10.1159/000064033     Document Type: Article

References (31)

1. Moertel CG, Fleming TR, MacDonald JS, Haller DG, Laurie JA, Tangen CM, Ungerleider JS, Emerson WA, Tormey DC, Glick JH, Veeder MH, Mailliard JA, Graff J: Fluorouracil plus levamisole as effective adjuvant therapy after resection of stage Ii colon carcinoma: A final report. Ann Intern Med 1995;122:321-326.
2. McLeod HL, Murray GI: Tumour markers of prognosis in colorectal cancer. Br J Cancer 1999;79:191-203.
3. Duffy MJ: Proteinases as prognostic markers in cancer. Clin Cancer Res 1996;2:613-618.
4. Andreasen PA, Kjøller L, Christensen L, Duffy M: The urokinase-type plasminogen activator system in cancer metastasis: A review. Int J Cancer 1997;72:1-22.
5. Ellis V, Pyke C, Eriksen J, Solberg H, Dano K: The urokinase receptor: Involvement in cell surface proteolysis and cancer invasion. Ann NY Acad Sci 1992;667:13-31.
6. Harbeck N, Alt U, Berger U, Kates R, Kruger A, Thomssen C, Janicke F, Gracff M, Schmitt M: Long-term follow-up confirms prognostic impact of PAI-1 and cathepsin D and L in primary breast cancer. Int J Biol Markers 2000;15:79-83.
7. Fockens JA, Peters HA, Look MP, Portengen H, Schmitt M, Kramer M, Brünner N, Jänicke F, Meijer-van Gelder ME, Henzen-Logmans SC, van Putten WLJ, Klijn JGM: The urokinase system of plasminogen activation and prognosis in 2,780 breast cancer patients. Cancer Res 2000;60:636-643.
8. Shiomi H, Eguchi Y, Tani T, Kodama M, Hattori T: Cellular distribution and clinical value of urokinase-type plasminogen activator, its receptor, and plasminogen activator inhibitor-2 in esophageal squamous cell carcinoma. Am J Pathol 2000;156:567-575.
9. Nekarda H, Schmitt M, Ulm K, Wenninger A, Vogelsang H, Becker K, Roder J, Fink U, Siewert J: Prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in completely dissected gastric cancer. Cancer Res 1994;54:2900-2907.
10. Fujii T, Obara T, Tanno S, Ura H, Kohgo Y: Urokinase-type plasminogen activator and plasminogen activator inhibitor-1 as a prognostic factor in human colorectal carcinomas. Hepatogastroenterology 1999;46:2299-2308.
11. Ganesh S, Sier C, Griffioen G, Vloedgraven H, Boer A, Welvaart K, van de Velde C, van Krieken J, Verheijen J, Lamers C, Verspaget H: Prognostic relevance of plasminogen activators and their inhibitors in colorectal cancer. Cancer Res 1994;54:4065-4071.
12. Kim SJ, Shiba E, Tsukamoto F, Izukura M, Tagushi T, Yoneda K, Tanji Y, Kimoto Y, Takai SI: The expression of urokinase type plasminogen activator is a novel prognostic factor in Dukes B and C colorectal cancer. Oncol Rep 1998;5:431-435.
13. Abe J, Urano T, Konno H, Erhan Y, Tanaka T, Nishino N, Takada A, Nakamura S: Larger and more invasive colorectal carcinoma contains larger amounts of plasminogen activator inhibitor type I and its relative ratio over urokinase receptor correlates well with tumor size. Cancer 1999;86:2602-2611.
14. Duffy MJ, Magure TM, McDermott EW, O'Higgins N: Urokinase plasminogen activator: A prognostic marker in multiple types of cancer. J Surg Oncol 1999;71:130-135.
15. Yang JL, Seetoo DQ, Wang Y, Ranson M, Berney CR, Ham JM, Russell PJ, Crowe PJ: Urokinase-type plasminogen activator and its receptor in colorectal cancer: Independent prognostic factors of metastasis and cancer-specific survival and potential therapeutic targets. Int J Cancer 2000;89:431-439.
16. Inuzuka K, OgataY, Nagase H, Shirouzu K: Significance of coexpression of urokinase-type plasminogen activator, and matrix metalloproteinase 3 (stromelysin) and 9 (gelatinase B) in colorectal carcinoma. J Surg Res 2000;93:211-218.
17. Smolarz B, Blasiak J, Kulig A, Romanowicz-Makowska H, Dziki A, Ulanska J, Pander B, Szewczyk T: Plasminogen activator inhibitor 1 (PAI-1) levels and gene promoter polymorphisms in subjects with colorectal cancer. J Exp Clin Cancer Res 2001;20:247-252.
18. Grøndahl-Hansen J, Ralfkiaer E, Kirkeby LT, Kristensen P, Lund LR, Dano K: Localization of urokinase-type plasminogen activator in stromal cells in adenocarcinomas of the colon in humans. Am J Pathol 1991;138:111-117.
19. Pyke C, Kristensen P, Ralfkiaer E, Grøndahl-Hansen J, Eriksen J, Blasi F, Dano K: Urokinase-type plasminogen activator is expressed in stromal cells and its receptor in cancer cells at invasive foci in human colorectal adenocarcinomas. Am J Pathol 1991;138:1059-1067.
20. Harvey S, Sait S, Xu Y, Bailey J, Penetrante R, Markus G: Demonstration of urokinase expression in cancer cells of colon adenocarcinomas by immunohistochemistry and in situ hybridization. Am J Pathol 1999;155:1115-1120.
21. Papadopoulou S, Scorilas A, Arnogianaki N, Tzimogiani A, Papanayiotou B, Agnanti N, Talieri M: Increased expression of gelatinase-A (MMP-2) in human colon cancer vs. normal colon mucosa. Tumor Biol 2001;22:383-389.
22. Costantini V, Sidoni A, Deveglia R, Cazzato OA, Bellezza G, Ferri I, Bucciarelli E, Nenci GG: Combined overexpression of urokinase, urokinase receptor, and plasminogen activator inhibitor-1 is associated with breast cancer progression. Cancer 1996;77:1079-1088.
23. Yamamoto M, Sawaya R, Mohanam S, Binday AK, Bruner JM, Oka K, Rao VH, Tomonaga M, Nicolson GL, Rao JS: Expression and localization of urokinase-type plasminogen activator in human astrocytomas in vivo. Cancer Res 1994;54:3656-3661.
24. Lowry OH, Roseborough NJ, Farr AL, Randall RJ: Protein measurement with folin-phenol reagent. J Biol Chem 1951;193:265-275.
25. Karameris A, Panagou P, Tsilalis T, Bouros D: Association of expression of metalloproteinases and their inhibitors with the metastatic potential of squamous-cell lung carcinomas. A molecular and immunohistochemical study. Am J Respir Crit Care Med 1997;156:1930-1936.
26. Patt YZ: Regional hepatic arterial chemotherapy for colorectal cancer metastasic to the liver: The controversy continues. J Clin Oncol 1993;11:815-819.
27. O'Connell MJ, Schaid DJ, Ganju V, et al: Current status of adjuvant chemotherapy for colorectal cancer. Cancer 1992;70:1732-1739.
28. Andreasen PA, Egelund R, Petersen HH: The plasminogen activation system in tumor growth, invasion, and metastasis. Cell Mol Life Sci 2000;57:25-40.
29. Provita P, Sordat I, Chaubert P, Saraga E, Tran-Thang C, Sordat B, Blum AL, Dorta G: Alterations in plasminogen activation correlate with epithelial cell dysplasia grading in colorectal adenomas. Br J Cancer 1998;77:297-304.
30. Buo L, Lyberg T, Jorgensen L, Johansen HT, Aasen AO: Location of plasminogen activator (PA) and PA inhibitor in human colorectal adenocarcinomas. Acta Pathol Microbiol Immunol Scand 1993;101:235-241.
31. Buo L, Meling GI, Karlsrud TS, Johansen HAT, Aasen AO: Antigen levels of urokinase plasminogen activator and its receptor at the tumor-host interface of colorectal adenocarcinomas are related to tumor aggressiveness. Hum Pathol 1995;26:1133-1138.